Trials to slow progression and prevent disease onset

Journal of Neural Transmission, Supplement

Volumn , Issue 59, 2000, Pages 243-249

  Thal, Leon J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CONJUGATED ESTROGEN; CYCLOOXYGENASE 2 INHIBITOR; ESTROGEN; GINKGO BILOBA EXTRACT; GROWTH FACTOR; HORMONE; IDEBENONE; INDOMETACIN; NERVE GROWTH FACTOR; SELEGILINE;

ALZHEIMER DISEASE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DISEASE COURSE; HUMAN; NONHUMAN; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; METHODOLOGY; NEUROLOGY; PREVENTIVE MEDICINE;

ALZHEIMER DISEASE; CLINICAL TRIALS; COGNITION DISORDERS; DISEASE PROGRESSION; HUMANS; NEUROLOGY; PREVENTIVE MEDICINE;

EID: 0033624427     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-6781-6_25     Document Type: Review

References (31)

1. Aisen PS, Davis KL, Berg JD, Schafer K, Campbell K, Thomas PG, Weiner MF, Farlow MR, Sano M, Grundman M, Thal LJ (for the Members of the Alzheimer's Disease Cooperative Study) (2000) A randomized controlled trial of prednisone in Alzheimer's disease. Neurology 54: 588-593
2. Behl C, Davis J, Cole GM, et al (1992) Vitamin E protects nerve cells from amyloid β protein toxicity. Biochem Biophys Res Commun 186: 944-950
3. Burke WJ, Roccaforte WH, Wengel SP, et al (1993) L-deprenyl in the treatment of mild dementia of the Alzheimer type: Results of a 15-month trial. J Am Geriatr Soc 41: 1219-1225
4. Day-Lollini PA, Stewart GR, Taylor MJ, Johnson RM, Chellman GJ (1997) Hyperplastic changes with the leptomeninges of the rat and monkey in response to chronic intracerebroventricular infusion of nerve growth factor. Exp Neurol 145: 24-37
5. Dekker AJ, Gage FH, Thal LJ (1992) Delayed treatment with nerve growth factor improves acquisition of a spatial task in rats with lesions of the nucleus basalis magnocellularis: Evaluation of involvement of different neurotransmitter systems. Neuroscience 48: 111-119
6. Fillit H, Weinreb H, Cholst I, et al (1986) Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type. Psychoneuroendocrinology 11: 337-345
7. Fisher W, Wictorin K, Bjorklund A, et al (1987) Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor. Nature 329: 65-68
8. Freedman M, Rewilak D, Xerri T, et al (1998) L-deprenyl in Alzheimer's disease: Cognitive and behavioral effects. Neurology 50: 660-668
9. Gillis JC, Benfield P, McTravish D (1994) Idebenone: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders. Drugs Aging 5: 133-152
10. Glasky AJ, Ritzmann RF, Prisecaru I, et al (1996) Elevation of brain mRNA for neurotrophins by oral AIT-082 in mice. Soc Neurosci 22: 751
11. Halliwell B, Gutteridge JMC (1985) Oxygen radicals in the nervous system. Trends Neurosci 8: 22-26
12. Hefti F (1986) Nerve growth factor promotes survival of septal cholinergic neurons after fimbrial transections. J Neurosci 14: 2155-2162
13. Hofferberth B (1994) The efficacy of EGb 761 in patients with senile dementia of the Alzheimer type, a double-blind, placebo-controlled study on different levels of investigation. Hum Psychopharmacol 9: 215-222
14. Honjo H, Ogino Y, Naitoh K, et al (1989) In vivo effects by estrone sulfate on the central nervous system-senile dementia (Alzheimer's type). J Steroid Biochem Mol Biol 34: 521-525
15. Jonhagen M, Wahlund LO, Amberla K, et al (1996) Nerve growth factors as a treatment of Alzheimer's disease. Neurobiol Aging 17: S160-161
16. LeBars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF, for the North American EGb Study Group (1997) A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo Biloba for dementia. JAMA 278: 1327-1332
17. Maurer K, Ihl R, Dierks T, Frolich L (1997) Clinical efficacy of Ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type. J Psychiatr Res 31: 645-655
18. Murphy TH, Schnaar RI, Coyle JT (1990) Immature cortical neurons are uniquely sensitive to glutamate toxicity by inhibition of cystine uptake. FASEB J 4: 1624-1633
19. Ohkura T, Isse K, Akazawa K, et al (1994) Evaluation of estrogen treatment in female patients with dementia of the Alzheimer type. Endocrinology J 41: 361-371
20. Olson L (1993) NGF and the treatment of Alzheimer's disease. Exp Neurol 124: 5-15
21. Packer L, Haramaki N, Kawabata T, et al (1995) Ginkgo biloba extract (EGb 761). In: Christen Y, Courtois Y, Droy-Lefaix MT (eds), Effect of Ginkgo Biloba extract (EGb 761) on aging and age-related disorders. Elsevier, Paris: 23-47
22. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 56: 303-308
23. Rogers J, Kirby LC, Hempelman SR, et al (1993) Clinical trial of indomethacin in Alzheimer's disease. Neurology 43: 1609-1611
24. Salmon DP, Thal LJ, N B, Heindel WC (1990) Longitudinal evaluation of dementia of the Alzheimer type: a comparison of three standardized mental status examinations. Neurology 40: 1225-1230
25. Sano M, Ernesto C, Thomas RG, et al (1997) A controlled trial of selegiline, α-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 336: 1216-1222
26. Schenk D, Barbour R, Dunn W, et al (1999) Immunization with Aβ attenuates Alzheimer's disease-like pathology in the PDAPP mouse. Nature 400: 173-177
27. Senin U, Parnetti L, Barbagallo-Sangiorgi G, et al (1992) Idebenone in senile dementia of Alzheimer type: A multicentre study. Arch Gerontol Geriatr 15: 249-260
28. Stern RG, Mohs RC, Davidson M, et al (1994) A longitudinal study of Alzheimer's disease: Measurement, rate, and predictors of cognitive deterioration. Am J Psychiatr 151: 390-396
29. Thal LJ, Carta A, Clarke WR, et al (1996) A one-year multicenter placebo-controlled study of acetyl-l-carnitine in patients with Alzheimer's disease. Neurology 47: 705-711
30. Weyer G, Erzigkeit H, Hadler D, Kubick S (1996) Efficacy and safety of idebenone in the long-term treatment of Alzheimer's disease: A double-blind, placebo-controlled multicentre study. Hum Psychopharmacol 11: 53-65
31. Winkler J, Ramirez GA, Kuhn G, et al (1997) Reversible induction of Schwann cell hyperplasia and sprouting of sensory and sympathetic neurites in vivo after continuous intracerebroventricular administration of nerve growth factor. Ann Neurol: 82-93